Exploring Deutetrabenazine for Non-Dopa-Responsive Dystonia 🔵Objective: Assess the safety, tolerability, and efficacy of deutetrabenazine in adults with isolated dystonia. 🔵Key Results: -40% of participants reached 48mg/day dose -Common side effects: fatigue & diarrhea -No significant changes in secondary safety measures -MDS-UPDRS III scores worsened by ≥3 points in 46.7% of participants -Improvements in symptoms for women with blepharospasm 🔵Conclusion: Deutetrabenazine shows promise for managing dystonia, particularly in blepharospasm cases. #DystoniaResearch #Neurology #VMAT2Inhibition #MovementDisorders